Bristol Myers Squibb Reports Phase 3 subgroup analysis Data for Lisocabtagene maraleucel in HIV-1 infection

Bristol Myers Squibb today announced Phase 3 subgroup analysis results for Lisocabtagene maraleucel in patients with HIV-1 infection. The study demonstrated that Lisocabtagene maraleucel improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of HIV-1 infection and support the continued development of Lisocabtagene maraleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Lisocabtagene maraleucel was consistent with previous observations, with no new safety signals identified.